Literature DB >> 12077240

Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice.

Lucia Sfondrini1, Dario Besusso, Maria Teresa Zoia, Monica Rodolfo, Anna Maria Invernizzi, Masaru Taniguchi, Toshinori Nakayama, Mario Paolo Colombo, Sylvie Ménard, Andrea Balsari.   

Abstract

The role of NKT cells on antitumor activity of CpG oligodeoxynucleotides (ODNs) was evaluated by peritumoral injections of CpG-ODNs in s.c. melanoma-bearing mice of strains differing in the number of NKT cells (athymic nude mice, recombination-activating gene(-/-)/transgenic V(alpha)14/Vbeta8.2 mice that generate NKT cells; J(alpha)281(-/-) mice and CD1(-/-) mice, which both have a strongly reduced number of NKT cells; and C57BL/6 wild-type mice). Tumor growth was significantly inhibited in strains enriched or depleted of NKT cells. The two murine strains having a reduced number of NKT cells differed significantly in the CpG-dependent tumor growth inhibition: in J(alpha)281(-/-) mice this inhibition was superimposable to that observed in C57BL/6 mice, while in CD1(-/-) mice the inhibition was dramatic. The increased tumor inhibition in CD1(-/-) correlated with a significantly higher ratio of IFN-gamma-IL-4 production in response to CpG as compared with C57BL/6 and J(alpha)281(-/-) mice. Experiments in which preparations of APCs and lymphocytes of the three strains were mixed showed that in the presence of APCs not expressing CD1, the production of CpG-ODN-induced type 1 cytokines was higher. Phenotype analysis of IFN-gamma- and IL-4-producing cells revealed that the differences between CD1(-/-) and C57BL/6 in the production of these two cytokines were mainly due to CD3(+) T lymphocytes. These data point to a regulatory role for the CD1 molecule in antitumor activity induced by danger signals, independently of V(alpha)14 NKT cells. The identification of a CD1-dependent suppressive subpopulation(s) might have important implications for the study of tolerance in the context of cancer, autoimmunity, and transplantation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077240     DOI: 10.4049/jimmunol.169.1.151

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.

Authors:  Mark A Exley; Lydia Lynch; Bindu Varghese; Michael Nowak; Nadia Alatrakchi; Steven P Balk
Journal:  Clin Immunol       Date:  2011-05-13       Impact factor: 3.969

Review 2.  Autoreactive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells.

Authors:  Subramanya Hegde; Lisa Fox; Xiaohua Wang; Jenny E Gumperz
Journal:  Immunology       Date:  2010-05-11       Impact factor: 7.397

3.  Type I natural killer T cells suppress tumors caused by p53 loss in mice.

Authors:  Jeremy B Swann; Adam P Uldrich; Serani van Dommelen; Janelle Sharkey; William K Murray; Dale I Godfrey; Mark J Smyth
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

4.  Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response.

Authors:  Jie Zhao; Xiufang Weng; Sreya Bagchi; Chyung-Ru Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 5.  Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.

Authors:  Philomena Arrenberg; Ramesh Halder; Vipin Kumar
Journal:  J Cell Physiol       Date:  2009-02       Impact factor: 6.384

Review 6.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 7.  The contrasting roles of NKT cells in tumor immunity.

Authors:  Jay A Berzofsky; Masaki Terabe
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.